Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Short-term Investments (2021 - 2025)

AVITA Medical (RCEL) has disclosed Short-term Investments for 4 consecutive years, with $7.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short-term Investments fell 63.63% year-over-year to $7.9 million, compared with a TTM value of $7.9 million through Dec 2025, down 63.63%, and an annual FY2025 reading of $7.9 million, down 63.63% over the prior year.
  • Short-term Investments was $7.9 million for Q4 2025 at AVITA Medical, up from $7.9 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $66.9 million in Q4 2023 and bottomed at $3.5 million in Q2 2025.
  • Average Short-term Investments over 4 years is $34.2 million, with a median of $32.6 million recorded in 2023.
  • The sharpest move saw Short-term Investments soared 178.13% in 2024, then crashed 90.51% in 2025.
  • Year by year, Short-term Investments stood at $61.2 million in 2022, then rose by 9.42% to $66.9 million in 2023, then plummeted by 67.38% to $21.8 million in 2024, then crashed by 63.63% to $7.9 million in 2025.
  • Business Quant data shows Short-term Investments for RCEL at $7.9 million in Q4 2025, $7.9 million in Q3 2025, and $3.5 million in Q2 2025.